Anturol® is a novel and proprietary transdermal gel system for the delivery of the anticholinergic drug, oxybutynin, approved Dec. 7, 2011 by the FDA for the management of overactive bladder. Anturol® is licensed to Watson Pharmaceuticals in the U.S and Canada. Antares is seeking qualified marketing partners for Anturol® in other major territories.
VIBEX™ MTX is being developed for rhematoid arthritis, a painful condition that affects over 2 million adults in the U.S. Antares expects to file an NDA for VIBEX™ MTX in 2012 and is seeking a licensing partner for territories outside of the U.S.
Our injection technology features four versatile platforms: needle-free injectors, mini-needle jet-injectors, pen injectors and auto-injectors. Our technologies offer pharmaceutical partners enhanced patient experiences for their injectable drugs.